Early Treatment with Rasagiline May Slow Parkinson's Disease Impairment

MAY 01, 2004
Susan Farley

Early initiation of a potential new treatment for Parkinson's disease may delay the progression of impairment associated with the disease, according to an article published in the April 2004 issue of Archives of Neurology. This conclusion was drawn from the results of the TEMPO trial ([TVP-1012] in the Early Monotherapy in Parkinson's disease Out-patients). In that trial, patients treated with once-daily rasagiline 1 or 2 mg per day for 12 months showed less impairment in Parkinson's disease features than patients whose treatment was delayed for 6 months. Impairment was measured by the patients' total Unified Parkinson's Disease Rating Scale (UPDRS) score. The UPDRS is commonly used to measure a patient's ability to perform mental and motor tasks and activities of daily living.



SHARE THIS SHARE THIS
0

Become a Respimat Top Performer 

Get to know RESPIMAT, the slow-moving mist inhaler from Boehringer Ingelheim Pharmaceuticals, Inc. 

Watch the RESPIMAT video and test your knowledge with a short multiple-choice quiz. When you get all the answers right, you’ll receive a certificate naming you a RESPIMAT T.O.P. Performer. Why not check it out today? 

 

Pharmacy Times Strategic Alliance
 

Pharmacist Education
Clinical features with downloadable PDFs


Next-Generation Pharmacist® Awards


3rd Annual Convenient Healthcare and Pharmacy Collaborative Conference


SIGN UP FOR THE PHARMACY TIMES NEWSLETTER
Personalize the information you receive by selecting targeted content and special offers.